DOCSLIB.ORG

RDL/Labcorp Cross Reference Guide

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
RDL/Labcorp Cross Reference Guide RDL/LabCorp Cross Reference Guide Profiles RDL Order Code RDL Test/Panel Name LabCorp Test No. LabCorp Test Name 1228 ANA 12 Plus Profile 520180 ANA 12 Plus Profile (RDL) 1230 ANA 12 Plus Profile, Do All 520175 ANA 12 Plus Profile, Do all (RDL) 1201 ANA 12 Profile 520188 ANA Profile 12 (RDL) 1206 ANA Profile 12, Do All 520299 ANA 12 Profile , Do All (RDL) 1100 ANA Profile I 520185 ANA Profile 11 (RDL) 1020 ANA Profile II 520185 ANA Profile 11 (RDL) 994 ANCA Panel 520149 ANCA Profile (RDL) 3003 Antiphospholipid Ab Panel I 500711 Lupus Anticoagulant/Cardiolipin Antibody (Esoterix) 3004 Antiphospholipid Ab Panel II 504400 Antiphospholipid Syndrome (APS), Comprehensive (Esoterix) 644 Anti-Saccharomyces 164657 Saccharomyces cerevisiae Profile 1292 Anti-Synthetase Panel 520193 Anti-Synthetase Profile (RDL) 996 Arthritis Panel 520205 Arthritis Profile (RDL) Autoimmune Liver Disease Panel, 558 520197 Autoimmune Liver Disease Profile (RDL) Comprehensive 1044 Celiac Disease Ab Panel 165142 Celiac Antibodies tTG IgA, EMA IgA, Total IgA with Reflex to tTG IgG 705 Hepatitis Panel II 322744 Hepatitis Panel, Acute ILDdxComplete (Interstitial Lung Disease 3008 520210 ILDdx Profile (RDL) Complete) Inflammatory Bowel Disease (IBD) Profile with Anti-Pancreatic Antibodies 1265 Inflammatory Bowel Disease Panel 520190 (RDL) 354 Interstitial Lung Disease Panel II 520202 Interstitial Lung Disease Profile (RDL) 1065 Lupus Activity Panel 520195 Lupus Activity Profile (RDL) 3002 Lupus Anticoagulant Panel 500070 Lupus Anticoagulant Profile (Esoterix) 342 Lupus Renal Activity Panel 520203 Lupus Renal Activity Profile (RDL) 1222 MyoMarker Panel 3 520080 MyoMarker® 3 Profile (RDL) 1223 MyoMarker Panel 3 Plus 520085 MyoMarker® 3 Plus Profile (RDL) 655 Pre-Biologic Therapy Assessment Panel 144441 Pre-Biologic Screening Profile 1600 Primary Biliary Cirrhosis Panel (PBC) 520192 Primary Biliary Cirrhosis (PBC) Profile (RDL) 1433 RAdx3 504509 RheumAssure® 1224 RAdx5 520091 RAdx5 Profile (RDL) 3006 Recurrent Pregnancy Loss Panel 502051 Recurrent Miscarriage / Fetal Demise Profile (Esoterix) Rheumatoid Arthritis Ab Panel, 520178 Rheumatoid Factor Isotypes, IgG, IgA, and IgM by EIA (RDL) 1836 Comprehensive 520008 Anti-CCP (Cyclic Citrullinated Peptide) Antibodies, IgG and IgA (RDL) 520075 Anti-Nuclear Antibodies by Indirect Flurorescent Antibody (IFA)(RDL) 1272 Rheumatology ANA Panel 520008 Anti-CCP (Cyclic Citrullinated Peptide) Antibodies, IgG and IgA (RDL) 520129 Rheumatoid Factor by Turbidmetry (RDL) 3001 Scleroderma Panel Plus 520130 Scleroderma Comprehensive Plus Profile (RDL) 1686 Scleroderma Panel, Comprehensive 520128 Scleroderma Comprehensive Profile (RDL) 3007 SeroNegRAdx3 520209 SeroNeg RAdx3 Profile (RDL) Sjogren's Abs: Anti-Ro Ab (SS-A) & Anti-La 715 520196 Sjogren’s Profile Plus (RDL) (SS-B) 1070 Vasculitis Panel 520293 Vasculitis Profile (RDL) 1 RDL/LabCorp Cross Reference Guide — Individual Tests RDL Order Code RDL Test/Panel Name LabCorp Test No. LabCorp Test Name 143 14-3-3 ETA Protein 504550 14.3.3 eta, Rheumatoid Arthritis 272 Aldolase 002030 Aldolase Anti-Nuclear Antibodies by Indirect Fluorescent Antibody (IFA), Body Fluid 205 ANA Titer & Pattern - Body Fluid 520143 (RDL) Anti-Nuclear Antibodies by Indirect Fluorescent Antibody (IFA), 287 ANA Titer & Pattern - CSF 520145 Cerebrospinal Fluid (RDL) Anti-Neutrophil Cytoplasmic Ab (ANCA) by Indirect Immunofluorescence 990 ANCA 520090 (IFA), (RDL) 147 Angiotensin Converting Enzyme (ACE) 010116 Angiotensin-converting Enzyme (ACE) Anti-Proliferating Cell Nuclear Antibodies by Indirect Fluorescent Antibody 73 Anti PCNA Ab (IFA) 520121 (IFA), (RDL) 10 Anti-Adrenal Ab (IFA) 520163 Anti-Adrenal Antibodies by Indirect Fluorescent Antibody (IFA), (RDL) 185 Anti-Alpha Fodrin Ab, IgA (EIA) 520295 Anti-Fodrin Antibodies, IgA (RDL) 184 Anti-Alpha Fodrin Ab, IgG (EIA) 520290 Anti-Fodrin Antibodies, IgG (RDL) 188 Anti-Alpha-Fodrin Ab, IgG & IgA 520134 Anti-Fodrin Antibodies, IgG & IgA (RDL) Anti-Beta-2 Glycoprotein 1 Abs, IgG, IgA 6 500590 β2-Glycoprotein I, IgA/G/M & IgM 62 Anti-Beta-2 Glycoprotein Ab, IgA (EIA) 163900 β2-Glycoprotein 1 Antibodies, IgA 60 Anti-Beta-2 Glycoprotein Ab, IgG (EIA) 163882 β2-Glycoprotein 1 Antibodies, IgG 61 Anti-Beta-2 Glycoprotein Ab, IgM (EIA) 163908 β2-Glycoprotein 1 Antibodies, IgM 458 Anti-C1Q Ab, IgG (EIA) 520147 Anti-C1Q Ab, IgG (RDL) 900 Anticardiolipin Ab, IgG (EIA) 500574 Anticardiolipin IgG 9 Anticardiolipin Ab, IgG, IgA & IgM 500967 Anti-Cardiolipin Antibodies, IgG, IgA, IgM (RDL) 901 Anticardiolipin Ab, IgM (EIA) 500570 Anticardiolipin IgM 165 Anti-CCP Ab (EIA) 520008 Anti-CCP (Cyclic Citrullinated Peptide) Antibodies, IgG and IgA (RDL) 12 Anti-Centromere Ab (IFA) 520065 Anti-Centromere Ab (RDL) 178 Anti-CEP-1 IgG (EIA) 520133 Anti-CEP-1 Ab, IgG (RDL) 578 Anti-Chromatin Ab, IgG (EIA) 520063 Anti-Chromatin Ab, IgG (RDL) 230 Anti-cN-1A Ab (EIA) 520061 Anti-cN-1A Ab (NT5c1A) IBM (RDL) 14 Anti-DNA Ab, (Single Stranded) 161422 Anti-DNA (Single-stranded) Antibodies, Quantitative, IgG 136 Anti-dsDNA Ab (EIA) 096339 Anti-dsDNA (Double-stranded) Antibodies 13 Anti-dsDNA Ab (Farr RIA) 520059 Anti-dsDNA (Double-stranded) Ab by Farr method (RDL) 38 Anti-dsDNA Ab, Crithidia, (IFA) 096346 dsDNA Antibody by IFA, Crithidia luciliae, with Reflex to Titer 914 Anti-ENA Abs 520174 Anti-ENA Abs (RDL) 52 Anti-Endomysial Ab, IgA (EIA) 164996 Endomysial Antibody, IgA 956 Anti-GBM Ab (EIA) 520137 Anti-Glomerular Basement Membrane Antibodies (RDL) 454 Anti-Gliadin Ab-DGP, IgA (EIA) 161646 Deaminated Gliadin Antibodies, IgA 453 Anti-Gliadin Ab-DGP, IgG (EIA) 161687 Deaminated Gliadin Antibodies, IgG 452 Anti-Gliadin Abs-DGP, IgG & IgA 163402 Celiac Disease Antibodies; Deamidated Gliadin Antibodies, (DGP) 15 Anti-Histone Ab (EIA) 520141 Anti-Histone Ab (RDL) 1809 Anti-HMGCR Ab (EIA) 520057 Anti-HMGCR Ab (RDL) 260 Anti-HSP-70 kD Ab, IgG (EIA) 520078 Anti-HSP70 (Human Heat Shock Protein 70 kD) Ab, IgG (RDL) 53 Anti-Islet Cell Ab (IFA) 160721 Antipancreatic Islet Cells 9003 Anti-Islet Cell Ab (Qual.) 160721 Antipancreatic Islet Cells 434 Anti-Jo-1 Ab (EIA) 520032 Anti-Jo-1 Ab (RDL) 129 Anti-Liver/Kidney Ab (EIA) 520087 Anti-Liver/Kidney Ab (RDL) 18 Anti-Mitochondrial Ab (IFA) 520103 Anti-Mitochondrial Ab by IFA (RDL) 428 Anti-Mitochondrial M2 Ab (EIA) 520117 Anti-Mitochondrial M2 Ab (RDL) 88 Anti-MPO Ab (EIA) 123006 Myeloperoxidase (MPO) 19 Anti-Myocardial Ab (EIA) 520160 Anti-Myocardial Antibodies by Indirect Fluorescent Antibody (IFA), (RDL) 20 Anti-Nuclear Ab by IFA (ANA) 520075 Anti-Nuclear Antibodies by Indirect Fluorescent Antibody (IFA), (RDL) 2 RDL/LabCorp Cross Reference Guide — Individual Tests RDL Order Code RDL Test/Panel Name LabCorp Test No. LabCorp Test Name 55 Anti-Ovary Ab (IFA) 520158 Anti-Ovary Antibodies by Indirect Fluorescent Antibody (IFA) (RDL) 645 Anti-Pancreatic Ab (IFA) 520119 Anti-Pancreatic Antibodies by Indirect Fluorescent Antibody (IFA) (RDL) 21 Anti-Parietal Cell Ab (IFA) 006486 Antiparietal Cell Antibody (APCA) 2002 Anti-PM/Scl-100 (EIA) 520007 Anti-PM/Scl-100 Ab (RDL) 2001 Anti-PM/Scl-75 Ab (EIA) 520051 Anti-PM/Scl-75 Ab (RDL) 89 Anti-PR-3 Ab (EIA) 520023 Anti-PR-3 Ab (RDL) 531 Anti-PS/PT Ab, IgG and IgM 504438 Anti-Phosphatidylserine/Prothrombin Complex, IgG and IgM 528 Anti-PS/PT Ab, IgM 504440 Anti-Phosphatidylserine/Prothrombin Complex, IgM 522 Anti-PS/PT Ab., IgG 504439 Anti-Phosphatidylserine/Prothrombin Complex, IgG 572 Anti-Ribosomal P Ab (EIA) 520123 Anti-Ribosomal P Protein Ab (RDL) 449 Anti-RNA Polymerase III Ab, IgG (EIA) 520021 Anti-RNA Polymerase III (RDL) 177 Anti-Sa IgG (EIA) 520081 Anti-Sa Ab, IgG (RDL) 176 Anti-SAE 1 IgG (EIA) 520011 Anti-SAE1 Ab, IgG (RDL) 577 Anti-Scl-70 Ab (EIA) 520012 Anti-Scl-70 Ab (RDL) 2003 Anti-Scl-70 Ab (ID) 018705 Antiscleroderma-70 Antibodies 57 Anti-Skin Ab, Pemphigus & Pemphigoid 082545 Antiskin Autoantibodies, Quantitative 579 Anti-SM Ab (EIA) 520013 Anti-Sm Ab (RDL) Anti-Smooth Muscle Antibodies by Indirect Fluorescent Antibody (IFA) 30 Anti-Smooth Muscle Ab (IFA) 520131 (RDL) 126 Anti-Soluble Liver Ag Ab (EIA) 520114 Anti-Soluble Liver Ag Ab (RDL) 1602 Anti-SP-100 Ab (EIA) 520112 Anti-SP-100 Ab (RDL) 1252 Anti-SS-A 52 kD Ab, IgG (EIA) 520015 Anti-SS-A 52kD Ab, IgG (RDL) 28 Anti-Striated Muscle Ab (IFA) 160184 Striational Antibodies 1332 Anti-Thyroglobulin Ab 500555 Anti-Thyroglobulin Antibodies 1333 Anti-TPO Ab 520018 Anti-TPO Ab (RDL) 574 Anti-U1-RNP Ab (EIA) 520034 Anti-U1 RNP Ab (RDL) 145 C1Q CIC 520147 Anti-C1Q Ab, IgG (RDL) 450 C3 Complement 520168 C3 Complement (RDL) 320 C3 Complement - Body Fluid 100149 Complement C3, Body Fluid 460 C4 Complement 520166 C4 Complement (RDL) 322 C4 Complement - Body Fluid 100339 Complement C4, Body Fluid 340 CPK 001362 Creatine Kinase,Total 314 CRP 006627 C-Reactive Protein (CRP), Quantitative 321 CRP Ultrasensitive 120766 C-Reactive Protein (CRP), High Sensitivity (Cardiac Risk Assessment) 1380 Cryoglobulins 120956 Cryoglobulin, Ql, Serum 1390 Cryoglobulins Characterization 120956 Cryoglobulin, Ql, Serum 276 EJ (RIPA) 520026 Anti-EJ Ab (RDL) 617 Epstein Barr Nuclear Ag, IgG (EBNA) 010272 Epstein-Barr Virus (EBV) Nuclear Antigen Antibodies, IgG 621 Epstein Barr Virus, Early Antigen Ab (EA) 096248 Epstein-Barr Virus (EBV) Antibodies to Early Antigen-Diffuse [EA(D)], IgG 104 ESR 005215 Sedimentation Rate, Modified Westergren 232 Fibrillarin (U3 RNP) (RIPA) 520019 Anti-U3 RNP Antibodies (Fibrillarin) (RDL) 241 FTA Ab 082370 Treponema pallidum Antibodies 1079 Glomerulonephritis Panel (GNP) 520194 Glomerulonephritis (GNP) Profile (RDL) 1601 GP-210 Ab (EIA) 520139 Anti-GP-210 Ab (RDL) 1722 Hepatitis A Virus Ab, IgG 006726 Hepatitis A Virus (HAV) Antibody, Total 721 Hepatitis A Virus Ab, IgG & IgM (HAV) 233635 HAVAb+M 1721 Hepatitis A Virus Ab, IgM 006734 Hepatitis A Antibody, IgM 1723 Hepatitis B Core Ab, IgM 016881 Hepatitis B Core Antibody, IgM 1724 Hepatitis B Core Ab, Total 006718 Hepatitis B Core Antibody, Total 3 RDL/LabCorp Cross Reference Guide — Individual Tests RDL Order Code RDL Test/Panel Name LabCorp Test No.
Load more

Recommended publications
  • Domino Effect in a Patient with Epstein-Barr Virus Infection and Autoimmunity: a Case Report Case Report Appointments Scheduled
    International Journal of Case Report Clinical Rheumatology Domino effect in a patient with Epstein- Barr Virus infection and autoimmunity: A case report The link between autoimmune diseases and viral infections has been characterized, but specific Margarite Matossian, Carrie mechanisms behind this association remain a current area of investigation. Whether viral infections Crook, Alec Goldberg, Anna trigger or unmask autoimmunity, or if the pathologies occur concurrently, is not yet completely Stathopoulos, Justin Tien, understood. Specifically, Epstein - Barr virus (EBV) is implicated in several autoimmune disorders, Sheela Sheth, Osaid Saqqa & including Systemic Lupus Erythematosus (SLE). It is hypothesized that common immunologic Christopher Dale Shamburger* pathways are activated in the two pathologic states. This case report is an example of this confusing Department of Medicine, Tulane University presentation, and the importance of recognizing the association between autoimmunity and viral Health Sciences Center, New Orleans LA infections. This patient presented with symptoms concerning for SLE and hepatic autoimmunity 70115, USA with serology suggesting a recent infection with EBV. Given this complicated presentation, it is *Author for correspondence: difficult to determine which disease state presented first in patients with evidence of both SLE and EBV infection and whether this information is clinically relevant for ongoing treatment and [email protected] monitoring. Here, we provide an in-depth discussion of current genomic and immunological research that supports the associations amongst these disease pathologies. Introduction by an intricate psychiatric history. Then Autoimmune diseases have increased in we discuss the contribution of infection to frequency in industrialized countries over autoimmune disease states and important recent years [1]. The etiology of autoimmune distinctions between autoimmune diseases diseases, a self-reactive adaptive immune and autoinflammatory responses.
    [Show full text]
  • Pediatric Motor Inflammatory Neuropathy: the Role Of
    brain sciences Case Report Pediatric Motor Inflammatory Neuropathy: The Role of Antiphospholipid Antibodies Claudia Brogna 1,2,*, Marco Luigetti 3 , Giulia Norcia 1, Roberta Scalise 1, Gloria Ferrantini 1, Beatrice Berti 1, Domenico M. Romeo 4, Raffaele Manna 5, Eugenio Mercuri 1 and Marika Pane 1 1 Pediatric Neurology and Nemo Clinical Centre, Fondazione Policlinico Universitario A. Gemelli IRCSS, Università Cattolica del Sacro Cuore, 00168 Roma, Italy; [email protected] (G.N.); [email protected] (R.S.); [email protected] (G.F.); [email protected] (B.B.); [email protected] (E.M.); [email protected] (M.P.) 2 Pediatric Neuropsichiatric Unit, ASL, 83100 Avellino, Italy 3 Institute of Neurology, Fondazione Policlinico Universitario A. Gemelli IRCSS, Università Cattolica del sacro Cuore, 00168 Roma, Italy; [email protected] 4 Pediatric Neurology, Fondazione Policlinico Universitario A. Gemelli IRCSS, Università Cattolica del Sacro Cuore, 00168 Roma, Italy; [email protected] 5 Periodic Fevers Research Centre and rare disease. Department of Internal Medicine, Fondazione Policlinico Universitario A. Gemelli IRCSS, Università Cattolica del Sacro Cuore, 00168 Roma, Italy; raff[email protected] * Correspondence: [email protected] Received: 4 February 2020; Accepted: 5 March 2020; Published: 7 March 2020 Abstract: We report the clinical case of a nine-year-old girl who presented with progressive motor neuropathy, revealed via the detection of a higher delay in F-wave recording using digitalized nerve conduction/electromyography. Since the lupus anticoagulant (LAC) positivity, detected using diluted Russell viper venom time (dRVVT), switched to persistent serological anticardiolipin immunoglobulin G (IgG) positivity, a possible non-thrombotic antiphospholipid antibody (aPL)-related clinical manifestation was suspected, and intravenous immunoglobulin treatment (IVIG) was started.
    [Show full text]
  • 32 Mechanism of Thrombosis in Antiphospholipid Syndrome: Binding to Platelets Joan-Carles Reverter and Dolors Tàssies
    32 Mechanism of Thrombosis in Antiphospholipid Syndrome: Binding to Platelets Joan-Carles Reverter and Dolors Tàssies Introduction Antiphospholipid antibodies (aPL) are related to thrombosis in the antiphospho- lipid syndrome (APS) [1, 2] and numerous pathophysiological mechanisms have been suggested involving cellular effects, plasma coagulation regulatory proteins, and fibrinolysis [3, 4]: aPL may act as blocking agents directly inhibiting antigen enzymatic or co-factor function of hemostasis; may bind fluid-phase antigens of hemostasis involved proteins and then decrease plasma antigen levels by clearance of immune complexes; may form immune complexes with their antigens that may be deposited in blood vessels causing inflammation and tissue injury; may cause dysregulation of antigen–phospholipid binding due to cross-linking of membrane bound antigens; and may trigger cell mediated events by cross-linking of antigen bound to cell surfaces or cell surface receptors [3, 4]. Moreover, several characteris- tics of the aPL, such as the concentration, class/subclass, affinity or charge, and several characteristics of the antigens, as the concentration, size, location or charge, may influence which of the theoretical autoantibody actions will occur in vivo [3]. Among the cellular mechanisms supposed to be involved, platelets have been considered as one of the most promising potential target for circulating aPL that may cause antibody mediated thrombosis as a part of the clinical spectrum of the autoimmune disorder of the APS. In the present chapter we will focus on the inter- actions that involve aPL binding to platelet membrane or platelet membrane bound antigens. Platelets as Target for aPL Platelets play a central role in primary hemostasis involving platelet adhesion to the injured blood vessel wall, followed by platelet activation, granule release, shape change, and rearrangement of the outer membrane phospholipids and proteins, transforming them into a highly efficient procoagulant surface [5].
    [Show full text]
  • Significant Factors Associated with Lupus Nephritis P Alba, L Bento, M J Cuadrado, Y Karim, M F Tungekar, I Abbs, M a Khamashta, D D’Cruz,Grvhughes
    556 EXTENDED REPORT Ann Rheum Dis: first published as 10.1136/ard.62.6.556 on 1 June 2003. Downloaded from Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis P Alba, L Bento, M J Cuadrado, Y Karim, M F Tungekar, I Abbs, M A Khamashta, D D’Cruz,GRVHughes ............................................................................................................................. Ann Rheum Dis 2003;62:556–560 Background: Lupus nephritis (LN) is a common manifestation in patients with systemic lupus erythema- tosus (SLE). Autoantibodies and ethnicity have been associated with LN, but the results are controver- sial. Objective: To study the immunological and demographic factors associated with the development of LN. Patients and methods: A retrospective case-control study of 127 patients with biopsy-proven LN, and 206 randomly selected patients with SLE without nephritis as controls was designed. All patients had attended our lupus unit during the past 12 years. Standard methods were used for laboratory testing. Results: Patients with LN were significantly younger than the controls at the time of SLE diagnosis See end of article for (mean (SD) 25.6 (8.8) years v 33.7 (12.5) years; p<0.0001). The proportion of patients of black eth- authors’ affiliations nic origin was significantly higher in the group with nephritis (p=0.02). There were no differences in ....................... sex distribution or duration of follow up. A higher proportion of anti-dsDNA, anti-RNP, anti-Sm, and Correspondence to: lupus anticoagulant (LA) was seen in the group with nephritis (p=0.002; p=0.005; p=0.0001; Dr M J Cuadrado, Lupus p=0.01, respectively).
    [Show full text]
  • Hepatic Manifestations of the Antiphospholipid Syndrome
    EDITORIAL Hepatic Manifestations of the Antiphospholipid Syndrome Key words: autoimmune hepatitis, Sjogren's syndrome, Budd- autoimmune hepatitis (7). Examinations prior to liver biopsy Chiari syndrome, nodular regenerative hyperpla- revealed a greatly prolonged APTT,and the patient was found sia to be positive for IgG anticardiolipin antibody and lupus anti- coagulant. However, this patient showedno signs of thrombo- sis or any other symptomssuggestive ofAPS. In this issue, Katayama et al (8) report a case of Sjogren's Antiphospholipid syndrome (APS) is characterized by the syndrome complicated with autoimmune hepatitis and APS. presence of antiphospholipid antibodies (anticardiolipin anti- bodies and/or lupus anticoagulant) in association with symp- See also p 73. toms including venous/arterial thromboses, recurrent fetal loss and thrombocytopenia. Thromboticepisodes mayoccur at any In previously reported cases of autoimmune hepatitis asso- part of the circulation system, hence, any organ may be in- ciated with the presence of antiphospholipid antibodies, anti- volved. As for hepatic involvement, the most well knownmani- nuclear antibody was present, but the presence of anti-SS-A festation ofAPSis Budd-Chiari syndrome, which is caused antibody or sicca symptomshave not been documented. There- mostly by obstruction of hepatic veins or inferior vena cava. fore, this case may possibly be the first documented case of Pelletier et al (1) have reported that of their 22 non-tumourous autoimmune hepatitis with APSand Sjogren's syndrome. Their Budd-Chiari patients, 4 had antiphospholipid antibodies with- patient had autoimmune hepatitis, and Sjogren's syndrome out other causes of hepatic vein thrombosis. Amongthese 4 confirmed by Schirmer's test and sialography. The patient patients, 2 seemed to have primary APS, i.e., no signs of other showed positive for (32-GPI dependent anticardiolipin antibody autoimmunediseases such as SLE.
    [Show full text]
  • Evaluation of Clinical and Laboratory Findings of 147 Patients with Systemic Lupus Erythematosus: the Relationship Between Anti-CCP and Arthritis
    J Surg Med. 2019;3(3):227-230. Research article DOI: 10.28982/josam.503850 Araştırma makalesi Evaluation of clinical and laboratory findings of 147 patients with systemic lupus erythematosus: The relationship between anti-CCP and arthritis Sistemik lupus eritematozuslu 147 hastanın klinik ve laboratuvar bulgularının değerlendirilmesi: Anti CCP ile artrit arasındaki ilişkinin incelenmesi Ali Ekin 1, Ayşe Ergüney Çefle 2 1 Department of Internal Medicine, Bingol Abstract State Hospital, Bingol, Turkey Aim: Anti-cyclic citrullinated peptide antibodies (Anti-CCP) is considered as a novel marker in the assessment of 2 Department of Internal Medicine, Division of Rheumatology, Faculty of Medicine, Kocaeli rheumatoid disorders. Some studies have emphasized the importance of anti-CCP in indicating erosive arthropathy in University, Kocaeli, Turkey Systemic Lupus Erythematosus (SLE), like Rheumatoid Arthritis (RA). These studies have reported that the chance of erosive arthritis development is significantly increased in anti-CCP-positive patients. This study aimed to investigate ORCID ID of the author(s) the relationship between anti-CCP and arthritis along with other clinical and laboratory parameters in patients with AE: 0000-0003-3692-1293 SLE. AEÇ: 0000-0002-3273-7969 Methods: A total of 147 SLE patients who had been admitted to Kocaeli University Medical Faculty, Department of Internal Medicine, Division of Rheumatology between January 2001 and October 2015 were included in this retrospective study. SLE diagnosis was verified according to American College of Rheumatology (ACR) and/or The Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) criteria. Patients whose diagnosis was not definite and not having anti-CCP were excluded. Results: Female/male ratio was found as 5.6, and the mean age was calculated as 43.9±11.85 years.
    [Show full text]
  • Northwestern Medicine
    How to put in your own Photo: Go to ‘View-Slide Master’ Go to ‘Insert-Picture’ Browse to the image you would like to place. Image should be 1024x768, 1200x900, or other 4:3 aspect ratio Select image and click OK Scale to full screen size if To live with lupus, necessary. Click image, go to ‘Format- we need to know Send to Back’ about lupus. Zineb Aouhab, MD Assistant Professor of Medicine Loyola University Medical Center 1 Division of Rheumatology Where did the word “lupus” come from? • The word ‘lupus’ is derived from the Latin word for “wolf”. • Named in the 13th century by the physician “Rogerius”. • He described the rash as erosive facial lesions as a consequence of a wolf's bite. • The facial rash is also called “Butterfly rash” because it resembles a butterfly shape. 2 What is lupus? • Lupus is an autoimmune disease. • It causes chronic inflammation in the body. • It can affect any organ of the body such as the kidneys, gastrointestinal tract, lungs, heart, and joints. 3 What happens in the body? • In normal people, the immune system forms antibodies to fight against infections. • In people with lupus, the immune system become overactive (like a bad allergic reaction) and produces a different types of antibodies. • These antibodies attack the person’s own organs causing organ damage. 4 Factors to consider in lupus • Lupus usually appears between the age of 15-45. • Lupus is much more common in females compared to males. Ratio 9:1 • Lupus is characterized by episodes of flares (when people feel very ill) and periods of remission (when people feel well and back to baseline).
    [Show full text]
  • 24 Lupus Anticoagulants: Mechanistic and Diagnostic Considerations Jef M
    24 Lupus Anticoagulants: Mechanistic and Diagnostic Considerations Jef M. M. C. Arnout and Jos Vermylen Introduction Antiphospholipid syndrome (APS) is defined as the association of antiphospholipid antibodies (aPL) with arterial or venous thrombosis, recurrent foetal loss, thrombo- cytopenia, or neurological disorders [1–3]. The gradual development of the notion APS started in the 1950ss with the recognition of two laboratory curiosities in a subset of patients with systemic lupus erythematosus (SLE). In these patients, rheumatologists frequently found a chronic biological false positive test for syphilis, whereas hematologists described a non-specific coagulation inhibitor manifested by prolongation of the whole blood clotting time and the prothrombin time, without reduction of any specific clotting factor then measurable [1–3]. The non-specific coagulation inhibitor which appeared not to be associated with a bleeding tendency was named the “lupus anticoagulant” by Feinstein and Rapaport [4] and was regarded as a laboratory curiosity until Bowie et al [5] drew the attention to the high prevalence of thrombotic complications in SLE patients with this “anticoagu- lant.” The LA was later also found to be associated with obstetric complications and thrombocytopenia [6]. Only in the 1980s did it became clear that antibodies interacting with anionic phospholipids are responsible for the in vitro LA effect and the chronic biological false positive syphilis serology [7]. This led to the development of better-defined LA tests and the so-called anticardiolipin test in which antibodies binding to solid phase cardiolipin (aCL) are measured [8, 9]. With these improved assays, the majority of SLE patients with a LA also had elevated aCL levels and a statistically significant relation between these 2 types of aPL was observed.
    [Show full text]
  • A Rare Case of Overlapping Syndrome of ANCA-Associated Glomerulonephritis and Copyright: Systemic Lupus Erythematosus © 2018 Jessica F, Et Al
    www.symbiosisonline.org Symbiosis www.symbiosisonlinepublishing.com Case Report Journal of Rheumatology and Arthritic Diseases Open Access A Rare Case of Overlapping Syndrome of ANCA- Associated Glomerulonephritis and Systemic Lupus Erythematosus Jessica Frey1* and Hajra Shah2 1Neurology Resident, Department of Neurology, West Virginia University, 1 Medical Center Drive, Morgantown WV 26505 USA 2Assistant Professor of Medicine, Department of Rheumatology, West Virginia University, 1 Medical Center Drive, Morgantown WV 26505 USA Received: June 15, 2018; Accepted: July 15, 2018; Published: July 23, 2018 *Corresponding author: Jessica Frey, MD, 99 Lakeside Drive, Morgantown WV 26508, USA. Tel: 412-523-8284; Fax: 304-598-6442; E-mail: [email protected] Abstract mechanisms, prognosis, and management of these two conditions, especially in context of one another. Introduction: Two very interesting rheumatologic diagnoses include Systemic Lupus Erythematosus (SLE) and Anti-Neutrophil Case Report Cytoplasmic Antibody (ANCA)-negative Vasculitis. It is rare to see these two conditions diagnosed in the same patient. This case analyzes We present the case of a 69 year old female with two the complex interactions between these two disease states. simultaneous new diagnoses of SLE and ANCA-negative Vasculitis. Case: This is the case of a 69 year old female who presented with shortness of breath, hematuria, and renal failure. Lab work was pulmonaryHer past medical hypertension. history Herwas presentingsignificant forsymptoms hypothyroidism, included gastro esophageal reflux disease, and recently diagnosed antibody, normal complement levels and a negative Vasculitis panel. one week of increasing shortness of breath, pleuritic chest pain, Renalsignificant biopsy for was elevated consistent ANA (1:1280),with ANCA-associated positive double-stranded Vasculitis (AAV).
    [Show full text]
  • Autoantibodies Diagnostic Tools for Autoimmune Disorders
    Autoantibodies Diagnostic tools for autoimmune disorders What are autoantibodies? Despite these limitations, autoantibodies are a valuable tool for the diagnosis (when considered with other clinical Autoantibodies bind non-foreign structures within us and have and laboratory information) and monitoring of many been found in most well-defined autoimmune disorders. They autoimmune disorders. also occur in other disorders with an inflammatory component and even in some malignant disorders as paraneoplastic phenomena. How is tissue injury caused in With a few important exceptions, autoantibodies have no direct autoimmune disorders? Are role in pathogenesis and their main value is as a ‘marker’ adding autoantibodies always pathological? weight to a clinical diagnoses. Much tissue damage in autoimmune diseases is probably Circulating forms of autoantibodies may be detected by mediated by T cells and their effector mechanisms, rather than assays on serum. Tissue-bound antibodies may also be by B cells and their products, autoantibodies. Systemic lupus detected by direct immunofluorescence studies of non-fixed erythematosus and other connective tissue disorders are biopsy specimens. characterised by polyclonal self-reactive B cell expansions. Normal immune system functions include the recognition of, and Do autoantibodies ever occur naturally, discrimination between, self and non-self targets and unleashing without clinical associations? of effector mechanisms, such as complement proteins, cytotoxic T cells, cytokines and other phagocytic cells onto non-self Low-level autoantibodies occur naturally and more commonly in targets. persons who are older, female, have chronic diseases and often a family history of autoimmune abnormalities. These natural Autoantibody production is a consequence of ongoing autoantibodies occur in low concentrations and have weak recognition of self targets by both T and B cells.
    [Show full text]
  • Colonic Ulcers in Propylthiouracil Induced Vasculitis with Secondary
    338 ADVERSE DRUG REACTION Postgrad Med J: first published as 10.1136/pgmj.2004.026104 on 5 May 2005. Downloaded from Colonic ulcers in propylthiouracil induced vasculitis with secondary antiphospholipid syndrome P D Gaburri, J M F Chebli, Aˆ Attalla, C M N Pereira, H L Bonfante, E V Martins Junior, A K Gaburri ............................................................................................................................... Postgrad Med J 2005;81:338–340. doi: 10.1136/pgmj.2004.026104 migratory polyarthritis, and fever during the past 15 months. A 48 year old white woman was admitted to the hospital She was taking propylthiouracil 100 mg a day over a period because of several bouts of migratory polyarthritis, weight of three years for hyperthyroidism. The symptoms had loss, fever, and abdominal pain over a period of 15 months. worsened in the past two months and an intense deteriora- She had been taking propylthiouracil 100 mg daily for three tion of general physical state occurred. She needed frequent years for hyperthyroidism treatment. A test for antineutrophil use of opioids orally in the past two weeks to relieve cytoplasmic autoantibodies (ANCA) was positive with a abdominal pain. There was no blood or mucus in the stools. perinuclear pattern of staining. Antiphospholipid antibodies On admission she was pale—haemoglobin concentration were also detected. Colonoscopy showed several ulcers on 9.4 g%—and her temperature was 38˚C. Blood pressure was intestinal mucosa and the biopsy specimen showed intense 120/80 mm Hg and a painful hepatomegaly was noticed. The microscopic vasculitis. The patient is well after methylpredni- spleen was felt 7 cm below the left costal margin and an solone pulse therapy and eight months of oral azathioprine.
    [Show full text]
  • Clinical and Laboratory Evaluation of Patients with Primary
    original Article Clinical and laboratory evaluation of patients with primary antiphospholipid syndrome according to the frequency of antinuclear antibodies (ANA Hep-2) Jozélio Freire de Carvalho1,2, Maria Teresa Correia Caleiro2, Margarete Vendramini3, Eloísa Bonfá4 ABSTRACT Objective: To evaluate the frequency of clinical and laboratory manifestations in patients with primary antiphospholipid syndrome (PAPS) with positive antinuclear antibodies (ANA Hep-2+) compared to those in whom this antibody is ne- gative (ANA Hep-2-). Patients and Methods: This is a transversal study with 58 patients (82.8% females) with PAPS. Demographic and clinical data, comorbidities, medications, and antiphospholipid antibodies were evaluated. Results: Twenty (34.5%) out of 58 patients were positive for ANA Hep-2. Comparing the group of patients ANA Hep-2+ with those that were ANA Hep-2-, it was observed that both groups of patients with APS did not show statistically significant differences regarding demographic data, as well as the duration of the disease. As for clinical and laboratorial mani- festations, the ANA Hep-2+ group showed higher frequency of deep venous thrombosis (85 versus 52.6%, P = 0.04), a statistically higher frequency of anticardiolipin IgG (85 versus 52.6%, P = 0.02), and a tendency for anticardiolipin IgM (80% versus 52.6%, P = 0.05), as well as greater medians of those antibodies [33 (0-128) versus 20 (0-120) GPL, P = 0.008] and [33 (0-120) versus 18,5 (0-120) MPL, P = 0.009]. Such difference was not observed regarding other manifestations of APS, presence of comorbidities, lifestyle, and medications used. Conclusions: Patients with PAPS with ANA Hep-2+ have a higher frequency of deep venous thrombosis and anticardiolipin IgG and IgM.
    [Show full text]